Asymptomatic virus sufferers lose antibodies sooner: study

Asymptomatic coronavirus sufferers appear to lose detectable antibodies sooner than people who have exhibited Covid-19 symptoms, according to one of the biggest studies of its kind in Britain published on Tuesday.

The findings by Imperial College London and market research firm Ipsos Mori also suggest the loss of antibodies was slower in 18–24 year-olds compared to those aged 75 and over.

Overall, samples from hundreds of thousands of people across England between mid-June and late September showed the prevalence of virus antibodies fell by more than a quarter.

The research, commissioned by the British government and published Tuesday by Imperial, indicates people’s immune response to Covid-19 reduces over time following infection.

James Bethell, a junior health minister, called it “a critical piece of research, helping us to understand the nature of Covid-19 antibodies over time”.

But scientists involved cautioned that a great deal remains unknown about people’s long-term antibody response to the virus.

“It remains unclear what level of immunity antibodies provide, or for how long this immunity lasts,” said Paul Elliott, of Imperial’s School of Public Health. 

The study involved 365,000 randomly-selected adults administering at home three rounds of finger prick tests for coronavirus antibodies between June 20 and September 28.  

The results showed the number of people with antibodies fell by 26.5 percent over the approximate three-month period.

Scaled up to a nationwide level, it meant the proportion of the English population with antibodies dropped from 6.0 percent to 4.4 percent, according to the study.

The decline coincided with the prevalence of the virus falling dramatically across England — and the rest of Britain — following a months-long national shutdown which was eased over the summer.

However, the research found the number of health care workers testing positive for antibodies did not change over time, potentially reflecting repeated, or higher initial, exposure to the virus. 

“This very large study has shown that the proportion of people with detectable antibodies is falling over time,” said Helen Ward, one of the lead authors.

“We don’t yet know whether this will leave these people at risk of reinfection with the virus that causes Covid-19, but it is essential that everyone continues to follow guidance to reduce the risk to themselves and others.”


Source Article

Read More

Global Cancer Antibodies Drug Conjugate Antibody Market To Reach USD 13 Billion By 2026

New Product Launches & Increasing Sales Of Existing Products To Drive the market Says Kuick Research

DELHI, India, Oct. 23, 2020 (GLOBE NEWSWIRE) — “Global Cancer Antibody Drug Conjugate Market, Price, Dosage & Clinical Trials Insight 2026” Report Highlights:

  • Global Cancer Antibody Drug Conjugate (ADC) Pipeline: 297 Drugs

  • Marketed Cancer Antibody Drug Conjugate: 9 Drugs

  • Antibody Drug Conjugate Marketed Opportunity: > US$ 13 Billion By 2026

  • Majority of Drug Trials Are For Second Line Therapy Or Greater

  • USA Dominates Cancer ADC Clinical Trials Landscape: > 180 Drugs

  • Tubulin Modulators Dominates Cancer ADC Trials: > 60 Drugs

  • Sales, Market Opportunity, Clinical Trials Graphs: > 100 Graphs

Download Report:

Download “Global Bispecific Antibody Market Opportunity, Drug Sales and Clinical Trials Insight 2026” Report:–trends-clinical-trials-emicizumab-hemlibra-blincyto–blinatumomab-sales

Worldwide cancer is among the leading cause of death. The unprecedented level of cancer cases at a global level is increasing due to the increase in life expectancy. In this overall scenario, researchers across the world have made significant development in the medical sector and have come up with antibody drug market as a mature therapeutic area for millions of patients. Despite of all the efforts that were put in improving old and traditional therapies, researchers were not able to provide and make a remarkable change in the cancer therapeutics market but the arrival of antibody drug market for the cancer patients have helped in achieving unexpected clinical results.

The better understanding of pathophysiology of cancer have led to the discovery of novel targets present on the surface of cancer cells and eventually antibody development against the target. The discovery of several novel molecular targets on the cancer cells have refreshed the overall expectations of providing better standard healthcare for millions of cancer patients across the world. Since the development of the market that focuses on antibody development, several noteworthy advances have been made, which have eventually marked the therapy as one of the most significant markets ever made in the cancer therapeutics sector.

The further classification of the market in monoclonal antibody market and bispecific antibody market have led to the emergence of the whole market as a therapy that focuses on improving the drug selectivity and reducing the overall adverse effects, which however are some of the mainstream challenges found in the cancer market. The current panorama of the market with respect to the research and development is focused on bringing major advancement to the overall clinical platform development. In addition, the drivers coupled with the market are also believed to be providing all the regulatory updates required for the smooth functioning of the market with respect to abolishing all the challenges that were perceived as difficult when resolved through other available cancer therapies.

The global pharmaceutical sector is currently poised towards antibody market for the overall growth and expansion of both the markets i.e. antibody drug market and cancer therapeutics market. In the next few years in line, the market is estimated to be growing and providing several trends for the patients,

Read More

Coronavirus antibodies estimated in less than 5% of French population: study

A nationwide study in France estimated that less than 5% of the population had coronavirus antibodies by mid-May.

The findings were posted ahead of peer review on Wednesday in medRxiv. Researchers from Public Health France, Department of Infectious Diseases, among others, said the study captures mild and asymptomatic cases that typically go unreported.

A nationwide study in France estimated that less than 5% of the population had coronavirus antibodies by mid-May.<br>

A nationwide study in France estimated that less than 5% of the population had coronavirus antibodies by mid-May.<br>


Study authors estimated that, throughout the first wave of the epidemic, nationwide prevalence of antibodies climbed from 0.41% in March to nearly 5% by May, which translates to 3,292,000 infections, according to the study.

Also, about 70% of those with antibodies had detectable neutralizing antibodies, which varied across ages and regions, authors wrote.

Blood samples were analyzed from 11,021 people and then extrapolated to the nationwide population.


“Seroprevalence estimates confirm that the nationwide lockdown substantially curbed transmission and that the vast majority of the French population remains susceptible to SARS-CoV-2 [the virus causing COVID-19 disease],” study authors wrote.

Antibody prevalence was highest in the area including Paris, where researchers noted the spread of infections happened earlier and more intensely.

“Our results are within the same order of magnitude as studies carried out at comparable epidemic stages in Europe,” the authors also wrote.

The study also found low infections among schoolchildren and suggested that the age group has restricted susceptibility and/or transmissibility.

“Our results provide a critical understanding of the progression of the first epidemic wave and provide a framework to inform the ongoing public health response as viral transmission is picking up again in France and globally,” they concluded. “Serological surveillance based on residual sera will continue to be used to provide timely seroprevalence estimates as the epidemic evolves and through the 2020-2021 winter season to monitor the progression of population-level immunity and guide public health response.”


Source Article

Read More

Global Monoclonal Antibodies Market to Surpass US$ 368.8 Billion by 2027, Says Coherent Market Insights (CMI)

According to Coherent Market Insights, the global monoclonal antibodies market is estimated to be valued at US$ 143.5 billion in 2020 and is expected to exhibit a CAGR of 14.4% over the forecast period (2020-2027).

Key Trends and Analysis of the Global Monoclonal antibodies Market:

Key trends in the market include increasing prevalence of cancer, rising regulatory approvals and launch of therapies, increasing research collaborations for the development of robust drugs pipeline, and adoption of collaboration strategies by the companies.

Rising incidence of cancer is expected to increase demand for infusion therapies, thereby contributing to significant growth of the monoclonal antibodies market. For instance, according to the World Cancer Research Fund International’s report, in 2018, breast cancer accounted for the second highest number of cancer cases worldwide, accounting for 2,088,849 new cases worldwide in 2018.

Moreover, increasing research collaborations for the development of robust drugs pipeline is a major factor that is expected to drive the market growth over the forecast period. Success of popular monoclonal antibodies such as Avastin, Herceptin, and Rituxan (revenue as US$ 6.8 Bn, US$ 7.1 Bn, and US$ 5.9 Bn, respectively in 2017 globally) has spurred manufacturers’ interest in these therapies. For instance, in 2018, Novartis AG announced entering into a partnership with MorphoSys and Galapagos for the commercialization and development of human immunoglobulin G1 (IgG1) monoclonal antibody targeting interleukin (IL)-17C.

Rising number of product approvals is expected to drive the market growth. For instance, in March 2019, AbbVie announced receiving approval for SKYRIZI (risankizumab) from Japanese Ministry of Health, Labour and Welfare (MHLW). Also, in March 2019, the U.S. FDA approved Trazimera (trastuzumab-gyyp) for the treatment of metastatic gastric adenocarcinoma and HER2 positive breast cancer.

Request Sample Copy of this Report @

Key Market Takeaways:

The global monoclonal antibodies market is expected to exhibit a CAGR of 14.4% over the forecast period, owing to adoption of collaboration strategy by the market players, which is expected to drive the market growth. For instance, in July 2020, UCB announced a license agreement with Roche and Genentech for the development and commercialization of UCB0107, an investigational monoclonal antibody drug, which is a potential treatment for patients with progressive supranuclear palsy (PSP) and Alzheimer’s disease.

An increasing number of government initiatives and funding for clinical trials of drugs, which can be used in the Covid-19 treatment, is projected to favor the market growth. For instance, in March 2020, the World Health Organization launched the ‘Solidarity’ trial, which is a multinational initiative for testing old and new drugs/therapies for treating Covid-19. The trial includes testing four therapies; remdesivir, chloroquine and hydroxychloroquine, lopinavir and ritonavir, lopinavir with ritonavir and interferon-beta.

Competitive Landscape:

Key players operating in the global monoclonal antibodies market include Pfizer Inc., Novartis AG, Bayer AG, Sanofi S.A., F. Hoffmann-La Roche AG, Eli Lilly and Co., Merck & Co., Inc., GlaxoSmithKline Plc., AbbVie Inc., Bristol-Myers Squibb, and Regeneron Pharmaceuticals Inc.

Buy-Now this Research Report @

Market Segmentation:

  • Global Monoclonal Antibodies Market, By Source:

    • Human

Read More